PayPal: Analysts Call For Earnings Per Share Of $0.86 For Q2 2022

PayPal Holdings (NASDAQ: PYPL) will be reporting its second quarter financial results today after market close. Analysts have a consensus $112.37 12-month price target on the company, via a total of 51 analysts, with nine analysts having strong buy ratings.

27 analysts meanwhile have buy ratings, 14 analysts have hold ratings and a single analyst has a sell rating on the stock. The street high comes from KGI Greater China with a $225 price target, and the lowest target sits at $75.

35 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 35 analysts is $6.78 billion; this number has been revised downwards continually since the start of the year. The highest revenue estimate is $6.96 billion, while the lowest is $6.59 billion.

Onto EBITDA estimates, there are currently 12 analysts who have second-quarter EBITDA estimates. The mean is currently $1.47 billion. The estimate has been revised lower since the start of the year. Street high is a $1.59 billion EBITDA estimate, and the lowest is $1.3 billion.

Analysts estimate that quarterly earnings per share will come in at $0.86, down from the $1.26 estimate at the start of the year. The street high estimate is $0.95, and the lowest estimate is $0.76 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver @ $36 & We’re Still 200M Oz Short | Paul Andre Huet – Americas Gold and Silver

Gold’s Wild Bull Run: Are Markets About to Break? | Mike McGlone

First Majestic Silver: The Santa Elena Mine

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Canaccord Drops Antibe’s Price Target To $0.70 Following Asset Sale

Antibe Therapeutics Inc. (TSX: ATE) recently reported their full-year 2022 results, wherein the company reported...

Friday, July 15, 2022, 02:25:00 PM

Trulieve: Canaccord Retains $97 Price Target Following Harvest Health Transaction

On October 1, Trulieve Cannabis (CSE: TRUL) announced that they completed their $1.75 billion acquisition...

Sunday, October 10, 2021, 01:03:00 PM

Curaleaf: Cormark Upgrades To Buy Rating, Canaccord, Haywood Raise Price Targets

After Curaleaf’s (CSE: CURA) record-breaking second-quarter numbers, analysts have upgraded their twelve-month price targets. Curaleaf...

Wednesday, August 19, 2020, 11:29:55 AM

BMO Downgrades Activision Blizzard, Says To “Take Profits, Step To Sidelines”

BMO’s analyst Gerrick Johnson is downgrading Activision Blizzard (NASDAQ: ATVI) to Market Perform and reducing...

Tuesday, October 13, 2020, 04:24:00 PM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM